dual FLT3/aurora kinase inhibitors (National Health Research Institutes)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual FLT3/aurora kinase inhibitors (National Health Research Institutes)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Serine/threonine-protein kinase Aurora-A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Health Research Institutes
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Health Research Institutes
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A